Search results
Results from the WOW.Com Content Network
The US Food and Drug Administration (FDA) approved durvalumab for certain types of bladder, lung, and biliary tract cancer: [6] [13] [14]. Adults with locally advanced or metastatic urothelial carcinoma who either have disease progression during or following platinum-containing chemotherapy or have disease progression within twelve months of neoadjuvant or adjuvant treatment with platinum ...
Gemcitabine, sold under the brand name Gemzar, among others, [1] is a chemotherapy medication used to treat cancers. [2] It is used to treat testicular cancer, [3] breast cancer, ovarian cancer, non-small cell lung cancer, pancreatic cancer, and bladder cancer. [2] [4] It is administered by intravenous infusion. [2]
Toripalimab is indicated in combination with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent locally advanced nasopharyngeal carcinoma. [ 1 ] [ 5 ] It is also indicated as a single agent for adults with recurrent unresectable or metastatic nasopharyngeal carcinoma with disease progression on or ...
The US Food and Drug Administration (FDA) approved it in March 2017, for the treatment of Merkel-cell carcinoma, [84] an aggressive type of skin cancer. The EMA approved it in September 2017, for the same indication. [86] This is the first FDA-approved treatment for metastatic Merkel-cell carcinoma, a rare, aggressive form of skin cancer. [84]
Kate Middleton is opening up about the long-term side effects of her cancer treatment.. On Tuesday, Jan. 14, the Princess of Wales spoke with staff during a surprise visit to the Royal Marsden ...
The country's top doctor wants a new warning added to alcohol that would alert drinkers about links to cancer, but don't expect cigarette-style warning labels any time soon.. U.S. Surgeon General ...
Durvalumab is FDA approved for the treatment of urothelial carcinoma and unresectable non-small cell lung cancer after chemoradiation. [ 33 ] Cosibelimab (Unloxcyt) by Checkpoint Therapeutics is a PD-L1 inhibitor developed by Dana Farber, and was approved in the United States in December 2024 for cutaneous squamous cell carcinoma .
Nearly four months after he announced he was cancer-free, Chicago Cubs Hall of Famer Ryne Sandberg announced that the cancer has spread to other organs in his body and he is set for more treatment.